why choose us

First received: July 14, 2022

Clinical Trial: Single-dose to Evaluate the Pharmacokinetics of GTX-101 and Subcutaneous Injectable Bupivacaine in Healthy Subjects

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: Postherpetic Neuralgia

Study Type: Interventional


Official Title: Parallel Study to Evaluate the Pharmacokinetics, Dose Proportionality, Safety and Tolerability of GTX-101 (Bupivacaine Hydrochloride Metered Dose Spray) and Subcutaneous Injectable Bupivacaine in Heal

Brief Summary: This is a single-center, randomized, single-dose, active-controlled study in healthy male and female subjects.The study will enroll subjects to evaluate the PK of 3 dose strengths (50 mg, 100 mg and 200 mg) of GTX-101 compared to Subcutaneous injection in healthy adult subjects.Blood samples for PK assessments will be collect at specified time points. Safety assessments will also be performed throughout the study.

Read more